Abstract:Several studies have shown that when purified from a tumor, certain heat shock proteins (HSPs) can function as effective vaccines against the same tumor by virtue of their ability to bind tumor-specific peptides. However, only a small fraction of the associated peptides would be expected to be immunogenic, in addition to which, the clinical application of this vaccine requires the availability of a surgical specimen of sufficient quantity for purification of the HSP. The present study describes a new approach for the development of natural HSP vaccines that do not have these limitations. This approach uses a recombinant HSP that is noncovalently bound to a recombinant tumor protein antigen by heat shock. HSP110 has been selected for this purpose, because it has been shown to be a highly efficient molecular chaperone in binding to large protein substrates. We show that a "natural chaperone complex" between HSP110 and the intracellular domain (ICD) of human epidermal growth factor receptor 2 protein (HER-2)/neu is formed by heat shock. This HSP110-ICD vaccine elicited both CD8(+) and CD4(+) T-cell responses against ICD as determined by an antigen-specific IFN-gamma production in an enzyme-linked immunospot assay (ELISPOT). In vivo depletion studies revealed that the CD8(+) T-cell response was independent of CD4(+) T-cell help. The HSP110-ICD complex also significantly enhanced ICD-specific antibody responses relative to that seen with ICD alone. No CD8(+) T cell or antibody response was detected against HSP110. The use of recombinant HSP110 to form natural chaperone complexes with large protein antigens represents a new and powerful approach for the design of protein-targeted cancer vaccines.

Recent Advances in Heat Shock Protein-Based Cancer Vaccines

Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

A Broadly Applicable, Personalized Heat Shock Protein-Mediated Oncolytic Tumor Vaccine.

Heat Shock Proteins HSP70 and GP96: Structural Insights

Cancer Immunotherapy: Stress Proteins and Hyperthermia

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

Advances in Cancer Vaccine Research

A novel anticancer approach: SEA-anchored tumor cells expressing heat shock protein 70 onto the surface elicit strong anticancer efficacy

Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective

Development Of A Recombinant Hsp110-Her-2/Neu Vaccine Using The Chaperoning Properties Of Hsp110

Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene.

Advance in Research on Heat Shock Proteins in Therapeutic Field of Tumor

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

Heat Shock Protein 70 / MAGE-1 Tumor Vaccine Can Enhance the Potency of MAGE-1–specific Cellular Immune Responses in Vivo

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.

Therapeutic cancer vaccines: advancements, challenges, and prospects

Radiation-induced Effect of Heat Shock Protein and Potential Clinical Application

[New Advances in Clinical Trials of Cancer Vaccines].

Heat Shock Proteins on Tumor Cell Surface as Target for Anti-Tumor Therapy (A Review)